OPKO Health, Inc. Operating Lease Liability
OPKO Health, Inc. (OPK) had Operating Lease Liability of $44.99 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-28
- 2026-06-30: Operating Lease, Liability $44.99M.
- 2026-03-31: Operating Lease, Liability $46.72M.
- 2025-12-31: Operating Lease, Liability $47.73M.
- 2025-09-30: Operating Lease, Liability $46.38M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $44.99M 10-Q/A · filed 2026-08-28 |
| 2026-03-31 | $46.72M 10-Q/A · filed 2026-08-28 |
| 2025-12-31 | $47.73M 10-K · filed 2026-02-26 |
| 2025-09-30 | $46.38M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $47.21M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $48.23M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $61.50M 10-K · filed 2025-03-03 |
| 2024-09-30 | $64.80M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $61.25M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $62.67M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $67.14M 10-K · filed 2024-03-01 |
| 2023-09-30 | $45.92M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $36.15M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $37.95M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $39.59M 10-K · filed 2023-02-27 |
| 2022-09-30 | $40.54M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $43.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $54.21M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $54.66M 10-K · filed 2022-03-01 |
| 2021-09-30 | $38.08M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $40.71M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $42.70M 10-Q · filed 2021-04-28 |
| 2020-12-31 | $38.79M 10-K · filed 2021-02-18 |
| 2020-09-30 | $37.30M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $39.06M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $40.15M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $39.70M 10-K · filed 2020-03-02 |
| 2019-09-30 | $36.24M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $30.05M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $33.74M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |